medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Epigenetic profiling of Italian patients identified methylation sites associated with hereditary Transthyretin amyloidosis

Antonella De Lillo,[1] Gita A. Pathak,[2,3] Flavio De Angelis,[1,2,3] Marco Di Girolamo,[4] Marco Luigetti,[5,6] Mario Sabatelli,[6,7] Federico Perfetto,[8] Sabrina Frusconi,[9] Dario Manfellotto,[4] Maria Fuciarelli,[1] Renato Polimanti[2,3*]

[1]Department of Biology, University of Rome Tor Vergata, Rome, Italy

[2]Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA

[3]VA CT Healthcare Center, West Haven, CT, USA

[4]Clinical Pathophysiology Center, Fatebenefratelli Foundation –'San Giovanni Calibita' Fatebenefratelli Hospital, Rome, Italy

[5]Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Rome, Italy

[6]Università Cattolica del Sacro Cuore, Rome, Italy

[7]'Centro Clinico NEMO adulti', Rome, Italy

[8]Regional Amyloid Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

[9]Genetic Diagnostics Unit, Laboratory Department, Careggi University Hospital, Florence, Italy

*Corresponding author:

Dr. Renato Polimanti. Department of Psychiatry, Yale University School of Medicine and VA CT Healthcare Center, VA CT 116A2, 950 Campbell Avenue, West Haven, CT 06516, USA. Tel: +1 203 932 5711 x5745; Fax: +1 203 937-3897; E-mail: renato.polimanti@yale.edu; ORCID: 0000-0003-0745-6046

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Hereditary Transthyretin (TTR) Amyloidosis (hATTR) is a rare life-threatening disorder caused by amyloidogenic coding mutations located in *TTR* gene. To understand the high phenotypic variability observed among carriers of *TTR* disease-causing mutations, we conducted an epigenome-wide association study (EWAS) assessing more than 700,000 methylation sites and testing i) *TTR* coding mutation carriers *vs*. non-carriers, and ii) Val30Met (rs28933979) carriers *vs*. carriers of other *TTR* mutations. In the first analysis, we observed a significant methylation change at cg09097335 site located in *Beta-secretase 2* (*BACE2*) gene (beta =-0.60, $p=6.26\times10^{-8}$). This gene is involved in a protein interaction network enriched for biological processes and molecular pathways related to amyloid-beta metabolism (Gene Ontology:0050435, q=0.007), amyloid fiber formation (Reactome HSA-977225, q=0.008), and Alzheimer's disease (KEGG hsa05010, $q=2.2\times10^{-4}$). Additionally, *TTR* and *BACE2* share APP (Amyloid-beta precursor protein) as a validated protein interactor. In the second analysis, we observed that Val30Met carriers have a significant hypomethylation at cg13139646 site located in *TTR* exonic region (beta=-2.18, $p=3.34\times10^{-11}$). A methylation quantitative trait locus analysis considering a 20 Kb region including *TTR* coding and non-coding regions suggested that *TTR* coding variants (Ile68Leu, rs121918085; Ala120Ser, rs876658108; Gly6Ser, rs1800458) have independent effects on cg13139646 methylation, while no independent effect was observed for non-coding variants. In conclusion, we provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of hATTR, highlighting the role of epigenetic regulation in this rare disorder.

Key words

hATTR, amyloidosis, Val30Met mutation, epigenetics, methylation, mQTL, modifier gene.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Background

Hereditary transthyretin amyloidosis (OMIM#105210) (hATTR) is a life-threatening disorder caused by transthyretin (TTR) misfolding and consequently amyloid fibril deposition in several tissues (e.g., peripheral nerves, heart, and gastrointestinal tract) (1, 2). This rare condition is characterized by extreme clinical heterogeneity including age of onset, penetrance, and clinical display (3-5). To date, more than 130 amyloidogenic mutations have been identified in the coding regions of the *TTR* gene, which are the cause of hATTR (6). The prevalence of hATTR is estimated to be approximately 1/100,000 (7). However, endemic areas of hATTR were identified in Portugal and Sweden (4, 5). Although both of these regions are affected by the same amyloidogenic mutation, Val30Met (rs28933979), their penetrance and age of onset are different: early age of onset and high penetrance in Portugal (4, 5, 8, 9); late age of onset and low penetrance in Sweden and in non-endemic countries (3, 10, 11). It has been hypothesized that hATTR phenotypic heterogeneity is due to the contribution of genetic and non-genetic factors involved in the complex genotype-phenotype correlation observed (12-18). Recent data strongly support the role of non-coding regulatory variation on *TTR* gene expression, as one of the mechanisms affecting the phenotypic manifestations observed in carriers of *TTR* amyloidogenic mutations (19-22). Among genomic regulatory features, epigenetic modifications are demonstrated to be key mechanisms in modulating a wide range of molecular functions and potential targets to develop novel treatments (23-25). Of several epigenetic modifications, DNA methylation is the most studied with respect to human traits and diseases (23). With respect to monogenic disorders, methylation studies investigated the role of epigenetic changes involved in the phenotypic expression observed among carriers of disease-causing mutations (26-28). Although epigenetic modifications have the potential to be involved in hATTR pathogenic mechanisms, to our knowledge no study explored methylation changes of patients affected by this life-threatening disease. In the present study, we conducted an epigenome-wide association study (EWAS) to identify DNA methylation associated with hATTR, investigating 48 carriers of *TTR* amyloidogenic mutations and 32 controls. We also tested whether there are significant epigenetic changes among carriers of different amyloidogenic mutations. The results obtained showed: i) hATTR confirmed

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

cases have significant methylation changes in modifier genes potentially involved in amyloidogenic processes; ii) carriers of Val30Met mutation showed a significant hypomethylation in *TTR* gene when compared to the carriers of other *TTR* amyloidogenic mutations.

Results

The epigenome-wide analysis testing the differences between 48 carriers of *TTR* amyloidogenic mutatinos and 32 controls identified a significant methylation site surviving false discovery rate multiple testing correction (FDR q<0.05) at the cg09097335 site located in *Beta-secretase 2* (*BACE2*) gene body (beta = -0.60, p=6.26×10^{-8}, FDR q=0.044; Table 1). Carriers of *TTR* amyloidogenic mutations showed a significant hypomethylation when compared to controls (Figure 1). To characterize the function of *BACE2* protein product, we investigated interactive proteins based on multiple experimental and computational evidence, identifying five candidates with medium-to-highest interaction confidence (Figure 2). These include FYN (FYN proto-oncogene, Src family tyrosine kinase; interaction score=0.809), BACE1 (Beta-secretase 1; interaction score=0.804), APP (amyloid-beta precursor protein; interaction score=0.430), IGHV3-11 (immunoglobulin heavy variable 3-11; interaction score=0.412), and ENSG00000259680 (uncharacterized protein similar to an immunoglobulin heavy variable 3/OR16 gene; interaction score=0.412). Among them, TTR showed the highest interaction with APP protein (interaction score=0.936). BACE2 protein interactive network (Figure 2) showed functional enrichments for several biological processes and molecular pathways (Table 2). Among the enrichments directly related to BACE2 function, we observed: Alzheimer's disease (KEGG hsa05010, FDR q=2.2×10^{-4}) related to the interaction of BACE2 with APP and BACE1; membrane protein ectodomain proteolysis (GO:0006509, FDR q=0.007) and amyloid-beta metabolic process (GO:0050435, FDR q=0.007) related to BACE2-BACE1 interaction; protein metabolic process (GO:0019538, FDR q=0.043) related to the interaction of BACE with APP, BACE1, FYN, and IGHV3-11. The interactions of other proteins within BACE2 interactive network also highlighted amyloid-related functional enrichments: amyloid fiber formation (Reactome HSA-977225, FDR q=0.008) and response to amyloid-beta (GO:1904645, FDR q=0.009) related to the interaction of APP with BACE1 and FYN, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Comparing the epigenetic profile of Val30Met carriers (N=33) *vs*. that of carriers of other *TTR* mutations (N=15), we identified a methylation site surviving the epigenome-wide multiple testing correction (Table 1). A CpG site located in the second exon of *TTR* gene (cg13139646) showed a significant hypomethylation in Val30Met carriers when compared with carriers of other *TTR* mutations (beta= -2.18, $p=3.34\times10^{-11}$, FDR $q=2.40\times10^{-5}$; Figure 3). To better understand whether the association of Val30Met with cg13139646 methylation is due to the effect of other regulatory variants in LD with this amyloidogenic mutation, we conducted a methylation quantitative trait locus (mQTL) analysis in a subset (N=15) of hATTR patients with complete sequencing of *TTR* coding and non-coding regions. Val30Met confirmed the strongest association with cg13139646 methylation (beta= -1.07, p=0.023; Additional File 1). None of the variants in LD with Val30Met showed stronger evidence of association (Additional File 2). Among the variants tested, Ile68Leu mutation was also associated with cg13139646 methylation: Ile68Leu carriers are hypermethylated when compared to the carriers of other mutations (beta=1.71, p= 0.045; Additional File 1). Suggestive evidences of associations were also observed for other *TTR* coding variants: Ala120Ser (beta=1.62, p=0.058) and Gly6Ser (rs1800458, beta=-1.14, p=0.069). These coding variants are not in LD each other (LD $r^2=0$; Additional File 2), indicating each association on cg13139646 methylation is independent. However, non-coding variants located in the upstream and downstream regions of *TTR* gene showed a perfect LD ($r^2=1$; Additional File 2) with Ile68Leu (LD with upstream variant rs72922940) and Ala120Ser (LD with downstream variant rs76431866 and upstream variants ss1360573709 and ss1360573712).

Finally, we explored whether the epigenetic changes identified are associated with symptoms reported by patients affected by hATTR. None of the associations reached a statistical significance (Additional File 3).

Discussion

hATTR is a rare multi-organ disorder caused by TTR misfolding and consequently amyloid deposition in several tissues (29). This life-threatening condition is characterized by high clinical heterogeneity with respect to age of onset, penetrance, and phenotypic manifestation (1-10, 29). Although *TTR*

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

amyloidogenic mutations are the cause of *TTR* misfolding, non-coding variation and modifier genes are hypothesized to be involved in wide variability of phenotypic manifestations observed in carriers of *TTR* disease-causing mutations (12, 15, 17-22). Epigenetic modifications (e.g., DNA methylation changes) could also play an important role in the molecular network regulating the hATTR amyloidogenic process (25). To explore this hypothesis, we conducted an EWAS investigating more than 700,000 methylation sites in 48 carriers of *TTR* amyloidogenic mutations and 32 non-carriers. A CpG site (cg09097335) located in *BACE2* gene was significantly hypomethylated in carriers when compared to non-carriers. This gene encodes Beta-secretase 2, a protein mainly known for its role in cleaving APP protein in amyloid-beta, which is a key factor involved in AD pathogenesis (30-32). Several studies showed that, unlike BACE1 that is the primary *β-secretase* protein cleaving APP to amyloid-beta, BACE2 is poorly expressed in the brain and its cleaving ability increases following an inflammatory response (33). APP processing occurs via three proteolytic cleavages caused by α- β- and γ-secretase (34). In non-amyloidogenic processes, α- and γ-secretases lead to the production of a smaller P3 fragment and APP intracellular domain, while, in the amyloidogenic pathway, β-secretase and γ-secretase produce amyloid-beta (34-38). Our results also showed a high-confidence interaction between APP and TTR. Numerous studies explored the interactions between these two amyloidogenic proteins, displaying a relevant biological role of TTR in amyloid-beta aggregation and clearance in AD patients (39-43). Specifically, altered TTR stability seems to reduce the clearance of amyloid-beta, increasing its toxicity in the brain (39-41). Metal ions and interaction with other proteins could also affect TTR stability (39). Interestingly, a significant association between amyloid-beta levels and AD was identified in AD patients with *TTR* Val30Met (39, 43). A putative amyloidogenic role of amyloid-beta in hATTR was also identified in a post-mortem analysis of a Val30Met carrier where both TTR and amyloid-beta were deposited in the cerebral leptomeningeal and cortical blood vessel walls with a part of the vessel wall occupied by a combination of TTR and amyloid-beta aberrant proteins (42). These previous findings strongly indicate an interplay between the pathogenic mechanisms involved in hATTR and AD. Our epigenome-wide study identified *BACE2* as a potential key factor in this interaction. As previously discussed, BACE2 protein plays a minor role in APP cleaving in the brain (32, 33), while its activity increases in peripheral

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

tissues under inflammatory response (33). Under this scenario, we hypothesize that the methylation change observed in the carriers of *TTR* mutations is due to BACE2 response to the inflammation induced by TTR amyloidogenic process in peripheral tissues (44).

In the epigenome-wide analysis testing carriers of *TTR* Val30Met *vs.* carriers of other *TTR* amyloidogenic mutations, we identified a CpG site, cg13139646, located in the second exon of *TTR* gene. Follow-up analyses showed that the methylation at this CpG site is independently associated with other *TTR* coding variants but not by non-coding variants. It is known that methylation profile differs between exonic and intronic regions (45). Although the transcriptional modulation is strongly regulated by the methylation of promoter regions, hypomethylation in exonic regions is associated with transcriptional upregulation while hypermethylation could promote the transcriptional silencing (45, 46). As mentioned, TTR amyloid accumulation causes tissue damage leading to inflammatory response activation, increasing reactive oxygen species (ROS) production and TTR oxidation (47). Val30Met mutation has been associated with increased S-nitrosylation during the amyloidogenic process, leading to the production of nitric oxide (NO), which increases the formation of amyloid fibrils (47). The association of Val30Met with these complex biochemical changes could explain the hypomethylation of cg13139646 in the carriers as a response to the specific amyloidogenic process induced by this mutation. We could also speculate that Val30Met and its induced biochemical changes are part of a feedback loop also including methylation changes and transcriptomic regulation of *TTR* gene. The independent effects observed with respect to other *TTR* coding variants could be related to the specific amyloidogenic process induced by them. We also observed suggestive evidence of association between cg13139646 methylation and Gly6Ser, a benign *TTR* coding variant. However, Levine and Bland (48) further explored the effect of this non-amyloidogenic mutation in individuals with autonomic and small fiber neuropathy, reporting a potential role of Gly6ser in the predisposition to neurodegenerative diseases.

Conclusions

Our study provided novel insights regarding the pathogenesis of hATTR, supporting the involvement of methylation changes in the amyloidogenic process induced by *TTR* disease-causing mutations. Further

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

studies will be needed to characterize specific mechanisms underlying the epigenetic associations, in particular, the potential role of amyloid-beta metabolic process and inflammatory response. The understanding of how methylation changes modulate the penetrance and the severity of *TTR* mutations could lead to the identification of novel targets to develop treatments and screening tools for the carriers.

Methods

Thirty-eight symptomatic patients and 10 asymptomatic *TTR* mutations carriers were recruited from three Italian centers for the treatment of systemic amyloidosis: "San Giovanni Calibita" Fatebenefratelli Hospital, Isola Tiberina – Rome, Fondazione Policlinico Universitario "A. Gemelli" – Rome and Careggi University Hospital – Florence (16-20). Thirty-two controls were recruited by the Department of Biology – University of Rome "Tor Vergata" (Table 3).

hATTR diagnosis was based on the presence of clinical signs and symptoms and the presence of an amyloidogenic mutation on *TTR* gene. The coding mutations identified include: Val30Met (rs28933979), Phe64Leu (rs121918091), Ile68Leu (rs121918085), Ala120Ser (rs876658108), and Val122Ile (rs76992529). One hATTR patient is a carrier of a mutation (rs36204272) in an intronic region with a putative clinical impact (48). Information regarding the organ involvements was collected for each patient: peripheral and nerve involvement (nerve conduction study); cardiac involvement (electrocardiographic and echocardiography anomalies); gastrointestinal involvement (gastric paresis, stypsis, or diarrhea); autonomic neurological involvement (orthostatic hypotension and urinary incontinence); ocular involvement (vitreous opacities): and carpal tunnel syndrome (median nerve decompression) (11, 49-51). The present study was approved under the protocol 39/18 by the Comitato Etico Indipendente, Fondazione Policlinico Tor Vergata – Rome, Italy.

DNA methylation analysis

DNA was extracted using the phenol/chloroform protocol (52) and purified through Amicon Ultra-0.5 mL Centrifugal Filters (EMD Millipore) to achieve a DNA concentration of 100 ng/µL. DNA concentration was checked via NanoDrop technology (ND-1000, Thermofisher Scientific) and Qubit Quantitation

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

technology (High Accuracy & Sensitivity, Thermofisher). DNA methylation analysis was executed in two phases: the EZ DNA Methylation kit (Zymo Research) was used to perform sodium bisulfite conversion; the Illumina Infinium Methylation EPIC Chip (with over 850,000 methylation sites; Illumina Inc.) was used to quantify DNA methylation according to the standard Illumina protocol. The methylation array analysis was performed at the Connecting bio-research and Industry Center, Trieste – Italy.

Preprocessing, quality control, and normalization

The raw signal intensity files were processed and cleaned using R 3.6 with ChAMP package (53). The ratio of methylated and unmethylated intensities from idat files was converted into beta values for further processing. The probes failing thresholds on detection value, bead count, sites near SNPs, probes that align to multiple positions, sex chromosomes and outliers were removed. None of the samples failed quality control. The remaining 718,509 probes for 80 individuals were normalized with BMIQ. Batch effects were assessed using singular vector decomposition and corrected with ComBat method (54). The genomic lambda of the case-control association was 1.03, calculated using QQPerm package (https://cran.r-project.org/web/packages/QQperm/index.html).

Blood cell type composition, genetic variability estimation, and smoking prediction

References-based method was employed to adjust for the heterogeneity due to the cell type composition of the whole blood samples investigated (55). This method uses specific DNA methylation signatures derived from purified whole blood cell-type as biomarkers of cell identity, to correct beta value dataset. Cell proportions for five cell-types (B cells, granulocytes, monocytes, natural killer cells, and T cells) were detected, and a linear regression was applied (53, 55).

To account for the genetic variability among the samples investigated, principal components (PCs) were calculate using the method proposed by Barfield, Almli (56). This approach allowed us to compute PCs based on CpGs selected for their proximity to SNPs. The data obtained can be used to adjust for population stratification in DNA methylation studies when genome-wide SNP data are unavailable (56).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Cigarette smoke has a very large effect on DNA methylation profile, triggering alteration at multiple CpGs (57). Consequently, smoking status needs to be considered as a potential confounder in epigenetic association studies. EpiSmokEr package was used to classify the smoking status of each participant on the basis of their epigenetic profile (58). Briefly, EpiSmoker is a prediction tool that provides smoking probabilities for each individual (never-smoker, former-smoker, and current smoker) using a set of 121 informative CpG sites (57).

Data analysis

We conducted two epigenome-wide analyses testing 718,509 methylation sites. First, we investigated the methylation changes between 48 cases (i.e., carriers of a *TTR* amyloidogenic mutation) and 32 controls. Second, we analyzed the epigenetic differences between Val30Met carriers (the most frequent mutation in our cohort; N= 33) and the carriers of other *TTR* mutations (N= 15). In both association analyses, we implemented a linear regression analysis including cell composition proportions, top three genetic PCs, epigenetically-determined smoking status, age, and sex as covariates. FDR method was applied to adjust the results for multiple testing (59) and the q-value < 0.05 was considered as the significance threshold. STRING v.11.0 (60) was used to identify protein interaction with the loci identified, considering experiments, co-expression, co-occurrence, gene fusion, and neighborhood as active sources and an interaction score higher than 0.4 (medium confidence). The protein interaction network was investigated further conducting functional enrichments association related to the protein-protein interactions identified considering Gene Ontologies (61) for biological processes and molecular pathways available from Reactome Database (62) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (63). FDR (q-value < 0.05) was applied to account for multiple testing assuming the whole genome as the statistical background. To detect associations between genetic variants and methylation changes in sites located in the chromosomal region of *TTR* gene, we investigated the association of epigenetic changes with genetic variability of 15 hATTR affected individuals analyzed previously (20). Plink 1.09 (64) was used to perform association analysis. Haploview (65) was used to determine linkage disequilibrium (LD) among tested variants.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

List of abbreviations

AD, Alzheimer disease; APP, amyloid beta precursor protein; hATTR, Hereditary transthyretin amyloidosis; BACE1, beta-secretase 1; BACE2, beta-secretase 2; EWAS, epigenome-wide association studies; FDR, false discovery rate; FYN, FYN proto-oncogene, Src family tyrosine kinase; IGHV3-11, immunoglobulin heavy variable 3-11; LD, linkage disequilibrium; mQTL, methylation quantitative trait loci; NO, nitric oxide; ROS, reactive oxygen species; TTR, transthyretin.

Declarations

Ethics approval and consent to participate

This study was approved under the protocol 39/18 by the Comitato Etico Indipendente, Fondazione Policlinico Tor Vergata – Rome, Italy. Informed consent was obtained from each participant involved.

Availability of data and materials

Data supporting the findings of this study are available within this article and its additional files.

Competing interests

Drs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest.

Funding

This study was supported by an Investigator-Initiated Research from Pfizer Inc. to the University of Rome Tor Vergata. Pfizer Inc. had no role in the study design, data analysis, and results interpretation of the present study.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Authors' contributions

ADL, FDA, MF, and RP were involved in study design. MDG, ML, MS, FP, SF, and DM conducted the recruitment and assessment of the participants. ADL, GAP, and RP carried out the statistical analysis. All authors were involved in the interpretation of the results. ADL and RP wrote the first draft of the manuscript and all authors contributed to the final version of the manuscript.

Acknowledgements

We thank the participants involved in this study and their caregivers.

Bibliography

1. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem. 2012;19(15):2324-42.
2. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
3. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181-6.
4. Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid. 2012;19 Suppl 1:71-2.
5. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29 Suppl 1:S3-S13.
6. Conceicao I, Damy T, Romero M, Galan L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3-9.
7. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
8. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet. 1995;60(6):512-21.
9. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003;40(11):e120.
10. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered. 1993;43(5):288-94.
11. Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013;34(7):1057-63.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

12. Alves-Ferreira M, Coelho T, Santos D, Sequeiros J, Alonso I, Sousa A, et al. A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal. Mol Neurobiol. 2018;55(5):3676-83.
13. Bonaiti B, Olsson M, Hellman U, Suhr O, Bonaiti-Pellie C, Plante-Bordeneuve V. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet. 2010;18(8):948-52.
14. Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Mendonca D, Alonso I, et al. Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J Hum Genet. 2016;24(5):756-60.
15. Soares ML, Coelho T, Sousa A, Batalov S, Conceicao I, Sales-Luis ML, et al. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet. 2005;14(4):543-53.
16. Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto L, Mauro A, et al. Most recent common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-phenotype correlation. Amyloid. 2015;22(2):73-8.
17. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes. Amyloid. 2013;20(4):256-62.
18. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis. Amyloid. 2014;21(3):154-62.
19. Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto LG, Mazzeo A, et al. Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis. BMC Genomics. 2017;18(1):254.
20. Iorio A, De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Sabatelli M, et al. Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet. 2017;25(9):1055-60.
21. De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Frusconi S, Manfellotto D, et al. Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. Hum Genet. 2019;138(11-12):1331-40.
22. Polimanti R, Nunez YZ, Gelernter J. Increased Risk of Multiple Outpatient Surgeries in African-American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. J Clin Med. 2019;8(2).
23. Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N Engl J Med. 2018;378(14):1323-34.
24. Yan H, Tian S, Slager SL, Sun Z, Ordog T. Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. Am J Epidemiol. 2016;183(2):96-109.
25. Szymczak S, Dose J, Torres GG, Heinsen FA, Venkatesh G, Datlinger P, et al. DNA methylation QTL analysis identifies new regulators of human longevity. Hum Mol Genet. 2020.
26. Clissold RL, Ashfield B, Burrage J, Hannon E, Bingham C, Mill J, et al. Genome-wide methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion. Clin Epigenetics. 2018;10(1):97.
27. Guay SP, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L. ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics. 2012;7(5):464-72.
28. Magalhaes M, Rivals I, Claustres M, Varilh J, Thomasset M, Bergougnoux A, et al. DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis. Clin Epigenetics. 2017;9:19.
29. Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag. 2020;16:109-23.
30. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6(1):27.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

31. Sassi C, Ridge PG, Nalls MA, Gibbs R, Ding J, Lupton MK, et al. Influence of Coding Variability in APP-Abeta Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One. 2016;11(6):e0150079.
32. Wang Z, Xu Q, Cai F, Liu X, Wu Y, Song W. BACE2, a conditional beta-secretase, contributes to Alzheimer's disease pathogenesis. JCI Insight. 2019;4(1).
33. Voytyuk I, Mueller SA, Herber J, Snellinx A, Moechars D, van Loo G, et al. BACE2 distribution in major brain cell types and identification of novel substrates. Life Sci Alliance. 2018;1(1):e201800026.
34. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3.
35. Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, et al. A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Mol Psychiatry. 2020;25(3):629-39.
36. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron. 2013;80(2):385-401.
37. Tambini MD, Norris KA, D'Adamio L. Opposite changes in APP processing and human Abeta levels in rats carrying either a protective or a pathogenic APP mutation. Elife. 2020;9.
38. Durrant CS, Ruscher K, Sheppard O, Coleman MP, Ozen I. Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. Cell Death Dis. 2020;11(2):98.
39. Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease. CNS Neurosci Ther. 2017;23(7):605-19.
40. Costa R, Goncalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity. FEBS Lett. 2008;582(6):936-42.
41. Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry. 2010;49(38):8276-89.
42. Sakai K, Asakawa M, Takahashi R, Ishida C, Nakamura R, Hamaguchi T, et al. Coexistence of transthyretin- and Abeta-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis. J Neurol Sci. 2017;381:144-6.
43. Xiang Q, Bi R, Xu M, Zhang DF, Tan L, Zhang C, et al. Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese. Mol Neurobiol. 2017;54(7):5192-200.
44. Azevedo EP, Guimaraes-Costa AB, Bandeira-Melo C, Chimelli L, Waddington-Cruz M, Saraiva EM, et al. Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol. 2019;19(1):146.
45. Chuang TJ, Chen FC, Chen YZ. Position-dependent correlations between DNA methylation and the evolutionary rates of mammalian coding exons. Proc Natl Acad Sci U S A. 2012;109(39):15841-6.
46. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, et al. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One. 2011;6(1):e14524.
47. Sharma M, Khan S, Rahman S, Singh LR. The Extracellular Protein, Transthyretin Is an Oxidative Stress Biomarker. Front Physiol. 2019;10:5.
48. Levine TD, Bland RJ. Incidence of nonamyloidogenic mutations in the transthyretin gene in patients with autonomic and small fiber neuropathy. Muscle Nerve. 2018;57(1):140-2.
49. Russo M, Mazzeo A, Stancanelli C, Di Leo R, Gentile L, Di Bella G, et al. Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. J Peripher Nerv Syst. 2012;17(4):385-90.
50. Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, et al. Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. J Neuromuscul Dis. 2015;2(s2):S39-S48.
51. Gagliardi C, Perfetto F, Lorenzini M, Ferlini A, Salvi F, Milandri A, et al. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. Eur J Heart Fail. 2018;20(10):1417-25.
52. Budowle B, Moretti, T., Smith, J., and Dizinno, J. DNA typing protocols: Molecular Biology and Forensic analysis. A Bio Techniques® Books Publications (Natick, MA: Eaton Publishing). 2000.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

53. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982-4.
54. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-27.
55. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.
56. Barfield RT, Almli LM, Kilaru V, Smith AK, Mercer KB, Duncan R, et al. Accounting for population stratification in DNA methylation studies. Genet Epidemiol. 2014;38(3):231-41.
57. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812.
58. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to determine smoking status from DNA methylation data. Epigenomics. 2019;11(13):1469-86.
59. Benjamini Y, Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57:289-300.
60. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D13.
61. The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330-D8.
62. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48(D1):D498-D503.
63. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353-D61.
64. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
65. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-5.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1: Methylation levels of cg09097696 site in carriers vs. non-carriers of amylodogenic mutations.

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2: BACE2 protein interaction network. Node colour of the protein is proportional to the interaction score with BACE2. Connector shade and width are proportional to the interaction confidence (highest, high, and medium).

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 3: Methylation levels of cg13139646 site in Val30Met carriers vs. carriers of other TTR amyloidogenic mutations.

Table 1: Significant methylation sites identified in the case-control analysis and in the Val30Met analysis. Information about cg probe (cgID), chromosome localization (chr), position (pos), CpG context, mapped gene, gene region, effect (beta), p value (p-value) and false discovery rate (FDR) q value are reported.

cgID	chr	pos	CpG context	Mapped gene	Gene region	beta	p-value	FDR
Cases vs Controls								
cg09097335	21	42597642	Open Sea	*BACE2*	Body	-0.60	6.26×10^{-8}	0.044
Val30Met vs non-Val30Met								
cg13139646	18	29172936	Open Sea	*TTR*	Body	-2.18	2.14×10^{-7}	7.86×10^{-5}

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2: Enrichments for gene ontologies (GO) of biological processes and for Reactome and KEGG molecular pathways (HSA and hsa, respectively).

ID	Description	Proteins	False Discovery Rate
hsa05010	Alzheimer's disease	APP,BACE1,BACE2	2.2E-04
HSA-2029481	FCGR activation	FYN,IGHV3-11	7.9E-04
HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	FYN,IGHV3-11	7.9E-04
HSA-983695	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	FYN,IGHV3-11	0.002
GO:0006509	membrane protein ectodomain proteolysis	BACE1,BACE2	0.007
GO:0050435	amyloid-beta metabolic process	BACE1,BACE2	0.007
GO:1902950	regulation of dendritic spine maintenance	APP,FYN	0.007
HSA-977225	Amyloid fiber formation	APP,BACE1	0.008
GO:1904645	response to amyloid-beta	APP,FYN	0.009
HSA-109582	Hemostasis	APP,FYN,IGHV3-11	0.010
GO:0106027	neuron projection organization	APP,FYN	0.010
GO:1900449	regulation of glutamate receptor signaling pathway	APP,FYN	0.010
HSA-202733	Cell surface interactions at the vascular wall	FYN,IGHV3-11	0.010
GO:0061098	positive regulation of protein tyrosine kinase activity	APP,FYN	0.017
GO:1903201	regulation of oxidative stress-induced cell death	APP,FYN	0.017
GO:0006897	Endocytosis	APP,FYN,IGHV3-11	0.018
GO:0007631	feeding behavior	APP,FYN	0.018
GO:0016358	dendrite development	APP,FYN	0.018
GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	FYN,IGHV3-11	0.018
GO:1901216	positive regulation of neuron death	APP,FYN	0.018
GO:1903426	regulation of reactive oxygen species biosynthetic process	APP,FYN	0.018
GO:1900180	regulation of protein localization to nucleus	APP,FYN	0.020
GO:0007612	Learning	APP,FYN	0.027
GO:0031347	regulation of defense response	APP,FYN,IGHV3-11	0.027
GO:2001056	positive regulation of cysteine-type endopeptidase activity	APP,FYN	0.027
GO:0030162	regulation of proteolysis	APP,FYN,IGHV3-11	0.031
GO:0051897	positive regulation of protein kinase B signaling	APP,FYN	0.031
GO:2000377	regulation of reactive oxygen species metabolic process	APP,FYN	0.031

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

HSA-168249	Innate Immune System	APP,FYN,IGHV3-11	0.032
HSA-76002	Platelet activation, signaling and aggregation	APP,FYN	0.032
GO:0050808	synapse organization	APP,FYN	0.034
GO:1901215	negative regulation of neuron death	APP,FYN	0.034
GO:0002684	positive regulation of immune system process	APP,FYN,IGHV3-11	0.037
GO:0050776	regulation of immune response	APP,FYN,IGHV3-11	0.037
GO:0002252	immune effector process	APP,FYN,IGHV3-11	0.041
GO:0007411	axon guidance	APP,FYN	0.041
GO:0019538	protein metabolic process	APP,BACE1,BACE2,FYN,IGHV3-11	0.043
GO:0006959	humoral immune response	APP,IGHV3-11	0.045

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 3: Description of the study population. Information about *TTR* amyloidogenic mutations, sex, age, epigenetically-determined smoking status (never smoker, NS; former smoker, FS; current smoker, CS), and epigenetically-estimated ranges of T cells (CD8T and CD4T), Natural Killer cells (NK), B cells, monocytes (Mono) and granulocytes (Gran) are reported.

TTR Mutation	*N*	*Sex Female (%)*	*Age Median (Min-Max)*	*Smoking*			*CD8T Median (Min –Max)*	*CD4T Median (Min –Max)*	*NK Median (Min –Max)*	*B cell Median (Min –Max)*	*Mono Median (Min –Max)*	*Gran Median (Min –Max)*
				NS	*FS*	*CS*						
Cases												
Val30Met	33	10 (30)	65 (31-88)	1	23	9	0.033 (-3.24×10^{-20} – 0.131)	0.118 (1.1×10^{-2} – 0.21)	0.033 (-3.81×10^{-19} – 0.127)	1.52×10^{-3} (-5.55×10^{-19} – 0.066)	0.082 (0.038 – 0.147)	0.634 (0.551 – 0.824)
Phe64Leu	8	1 (12)	70 (48-75)	0	4	4	4.02×10^{-3} (1.07×10^{-18} – 1.112)	0.127 (6.9×10^{-2} – 0.228)	0.014 (1.96×10^{-20} – 0.099)	3.13×10^{-3} (-2.17×10^{-19} – 0.021)	0.085 (0.057 – 0.107)	0.65 (0.46 – 0.704)
Ala120Ser	2	2 (100)	67-68	0	2	0	-3.34×10^{-20} – 0	0.068 – 0.11	8.1×10^{-3} – 1.28×10^{-1}	0 – 5.1×10^{-3}	0.092 – 0.11	0.56 – 0.74
Ile68Leu	3	0	53 (30-62)	0	0	3	0	0.142 (0.07 – 0.16)	0.038 (0.013 – 0.041)	4.4×10^{-3} (3.8×10^{-3} – 5.1×10^{-3})	0.083 (0.096 – 0.147)	0.59 (0.603 – 0.7[illegible])
Val122Ile	1	0	80	0	0	1	0	0.23	0.042	0.005	0.071	0.55
rs36204272*	1	0	65	0	1	0	0.069	0.14	0.052	0.006	0.129	0.505
Controls												
–	32	19 (59)	37 (20-76)	0	27	5	0.015 (8.45×10^{-19} – 0.13)	0.16 (0.045 – 0.34)	0.044 (-2.68×10^{-19} – 0.18)	0.014 (1.08×10^{-19} – 0.091)	0.092 (0.051 – 0.13)	0.571 (0.41 – 0.7[illegible])

*non-coding variant of uncertain clinical impact

medRxiv preprint doi: https://doi.org/10.1101/2020.04.13.20064006; this version posted April 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.